What stocks measure up in the £74bn slimming wars
The £25.2billion weight-loss drug market is too chunky to be ignored – if the latest forecast from Goldman Sachs is to be believed. The US bank says that 2026 is set to be a 'pivotal year for the development of the obesity sector'. By 2030, …